Alnylam Pharmace. buy Barclays PLC
Summary
This prediction is currently active. With a performance of -8.81%, the BUY prediction by Barclays_PLC is trending in the wrong direction. This prediction currently runs until 02.08.25. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Alnylam Pharmace. | -6.395% | -6.395% |
iShares Core DAX® | -3.429% | 3.133% |
iShares Nasdaq 100 | -6.121% | -1.433% |
iShares Nikkei 225® | -7.364% | 1.018% |
iShares S&P 500 | -4.366% | 0.247% |
Comments by Barclays_PLC for this prediction
In the thread Alnylam Pharmace. diskutieren
Stopped prediction by Barclays_PLC for Alnylam Pharmace.
Alnylam Pharmace.
25.06.24
25.06.25
06.09.24